Cg Oncology, Inc. CGON Stock Forecast
AI-powered price prediction and analysis for Cg Oncology, Inc. · Total · absolute moveSwitch to Alpha
See CGON's Exact Price Target · Create a free account and follow this stock to unlock its full AI forecast — 3 stocks free.
Price Chart
Key Statistics
About Cg Oncology, Inc.
Cg Oncology, Inc. (CGON) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry.
Latest News
- CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer
- CG Oncology, Inc. (CGON) Reports Q1 Loss, Tops Revenue Estimates
- CG Oncology, Inc. (CGON) Presents at Bank of America Global Healthcare Conference 2026 Transcript
- Sign up free to read all 8 articles →
Where CGON sits on the market map
Biological Products, (No Diagnostic Substances) Peers
Companies sharing the same SEC industry code, one row per issuer, largest first - a classification match, not a curated list of competitors.
| Company | AI Signal | Market Cap | P/E |
|---|---|---|---|
| CGON Cg Oncology, Inc. | ▲ | $5.48B | – |
| AMGN Amgen Inc | ▼ | $230.37B | 26.4x |
| GILD Gilead Sciences, Inc. | ▶ | $190.38B | – |
| MRNA Moderna, Inc. | ▲ | $90.35B | – |
| ARGX Argenx Se | ▼ | $50.64B | – |
| RVMD Revolution Medicines, Inc. | ▲ | $41.48B | – |
| BIIB Biogen Inc. | ▼ | $34.37B | 23.6x |
| BNTX Biontech Se | ▶ | $22.42B | – |
| MESO Mesoblast Ltd | ▶ | $17.88B | – |
| EXEL Exelixis, Inc. | ▲ | $15.11B | – |
| NBIX Neurocrine Biosciences Inc | ▼ | $13.82B | 19.6x |
| HALO Halozyme Therapeutics, Inc. | ▶ | $13.26B | 32.1x |
| TECH Bio-Techne Corp | ▼ | $11.37B | 62.5x |
| IBRX Immunitybio, Inc. | ▲ | $10.50B | – |
| RGEN Repligen Corp | ▲ | $10.06B | 242.1x |
| PCVX Vaxcyte, Inc. | ▲ | $10.05B | – |
| QGEN Qiagen N.V. | ▼ | $9.88B | – |
| KRYS Krystal Biotech, Inc. | ▶ | $9.79B | 40.5x |
| TWST Twist Bioscience Corp | ▲ | $9.29B | – |
| KYMR Kymera Therapeutics, Inc. | ▲ | $8.88B | – |
| IOVA Iovance Biotherapeutics, Inc. | ▲ | $6.44B | – |
| IMVT Immunovant, Inc. | ▲ | $5.76B | – |
| KOD Kodiak Sciences Inc. | ▲ | $5.10B | – |
| CRSP Crispr Therapeutics Ag | ▲ | $4.86B | – |
| SRRK Scholar Rock Holding Corp | ▲ | $4.82B | – |
| ADPT Adaptive Biotechnologies Corp | ▲ | $4.09B | – |
| RLAY Relay Therapeutics, Inc. | ▲ | $3.74B | – |
| TARS Tarsus Pharmaceuticals, Inc. | ▲ | $3.17B | – |
| DNLI Denali Therapeutics Inc. | ▲ | $2.86B | – |
| DBVT Dbv Technologies S.A. | ▼ | $2.63B | – |
| BEAM Beam Therapeutics Inc. | ▲ | $2.44B | – |
| ADMA Adma Biologics, Inc. | ▲ | $2.32B | 13.7x |
| NVAX Novavax Inc | ▲ | $2.08B | – |
| VCEL Vericel Corp | ▶ | $2.06B | 85.2x |
| BCRX Biocryst Pharmaceuticals Inc | ▲ | $2.06B | – |
| RXRX Recursion Pharmaceuticals, Inc. | ▲ | $2.00B | – |
| VIR Vir Biotechnology, Inc. | ▲ | $1.80B | – |
| SCNI Scinai Immunotherapeutics Ltd. | ▶ | $1.71B | – |
| ALVO Alvotech | ▶ | $1.61B | – |
| IMCR Immunocore Holdings Plc | ▶ | $1.46B | – |
| MAZE Maze Therapeutics, Inc. | ▲ | $1.46B | – |
| COAG Hemab Therapeutics Holdings, Inc. | ▲ | $1.40B | – |
| TSHA Taysha Gene Therapies, Inc. | ▲ | $1.14B | – |
| VOR Vor Biopharma Inc. | ▶ | $1.13B | – |
| REPL Replimune Group, Inc. | ▲ | $1.07B | – |
| JATT Zura Bio Ltd | ▼ | $1000M | – |
| VALN Valneva Se | ▼ | $965M | – |
| IMTX Immatics N.V. | ▲ | $938M | – |
| MGTX Meiragtx Holdings Plc | ▶ | $904M | 11.4x |
| CGEM Cullinan Therapeutics, Inc. | ▲ | $878M | – |
| GLUE Monte Rosa Therapeutics, Inc. | ▲ | $839M | – |
| ODTX Odyssey Therapeutics, Inc. | ▲ | $798M | – |
| DNA Ginkgo Bioworks Holdings, Inc. | ▲ | $776M | – |
| SANA Sana Biotechnology, Inc. | ▲ | $698M | – |
| CADL Candel Therapeutics, Inc. | ▲ | $694M | – |
| FDMT 4d Molecular Therapeutics, Inc. | ▲ | $674M | – |
| AURA Aura Biosciences, Inc. | ▲ | $640M | – |
| SLDB Solid Biosciences Inc. | ▲ | $586M | – |
| PRME Prime Medicine, Inc. | ▲ | $568M | – |
| RGNX Regenxbio Inc. | ▲ | $454M | – |
FAQ
Is Cg Oncology, Inc. a good stock to buy?
Our AI analyzes Cg Oncology, Inc. daily. Check the signal above for the latest recommendation. Always do your own research before investing.
How accurate are Cg Oncology, Inc. predictions?
A per-ticker accuracy statistic for CGON is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are forecasts updated?
Cg Oncology, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Ready to invest smarter? · Join thousands of investors using AI-powered stock predictions
Sign Up FreeLooking for a deeper analysis of Cg Oncology, Inc.? View full institutional-grade analysis on Intratio →
AI predictions are based on historical patterns and should not be the sole basis for investment decisions. Past performance does not guarantee future results. Always do your own research.